팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2021-07-19 [공지사항] 주주 여러분께 (5)
      2021-06-28 [공지사항] 주주 여러분께 (4)
      2021-06-07 [공지사항] 주주 여러분께 (3)
      2021-05-21 [공지사항] 주주 여러분께 (2)
      2021-05-14 [공지사항] 주주 여러분께
  • Press Release

      2021-04-12 큐리언트, AACR서 'Q901' 내성 유방암 치료효과 발표
      2021-03-22 '결핵약 국산화' 채영복 박사 "韓 결핵 1위…정부 지원 확대해야"
      2021-01-26 Qurient Enrolls First Patient in Q702 U.S. Phase 1 Study
      2021-01-26 큐리언트, 면역항암제 美 임상 1상 환자 투약 개시
      2021-01-14 FDA grants orphan drug designation to Qurient’s ulcer treatment
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file